SciSparc initiates SCI-120 clincal trial in pediatrics with ASD

SciSparc announced the initiation of a pivotal clinical trial for its drug candidate, SCI-210, at the Soroka University Medical Center. SCI-210 is designed to help control symptoms of Autism Spectrum Disorder and is an innovative proprietary combination of cannabidiol and SciSparc’s Palmitoylethanolamide, the active ingredient of its proprietary CannAmide. The study will evaluate the safety, tolerability, and efficacy of SCI-210, in comparison to CBD monotherapy in treating ASD. Designed as a randomized, double-blind, placebo-controlled trial with a cross-over study, the trial will span 20 weeks and involve 60 children between 5-18 years old. The trial’s primary efficacy endpoints include three rigorous assessments: the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire; the Clinical Global Impressions-Improvement scale, administered by healthcare professionals; and the determination of the effective therapeutic dosage. The trial was designed in collaboration with the National Autism Research Center, Israel’s leading institution for autism research.